Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Adoptive immunotherapy for myeloid malignancies

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Ballen KK, Becker PS, Emmons RVB, Fitzgerald TJ, Hsieh CC, Liu Q et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 2002; 100: 442–450.

    CAS  Article  Google Scholar 

  2. 2

    Colvin GA, Berz D, Ramanathan M, Winer ES, Fast L, Elfenbein GJ et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant 2009; 15: 421–431.

    CAS  Article  Google Scholar 

  3. 3

    Guo M, Hu K-X, Yu C-L, Sun Q-Y, Qiao J-H, Wang D-H et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011; 117: 936–941.

    CAS  Article  Google Scholar 

  4. 4

    Guo M, Hu K-X, Liu G-X, Yu C-L, Qiao J-H, Sun Q-Y et al. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up. J Clin Oncol 2012; 30: 4084–4090.

    Article  Google Scholar 

  5. 5

    Grupp SA, Porter DL, Teachey DT, Barrett DM, Chew A, Suppa E et al. CD19-redirected chimeric antigen receptor T (CART19) cells induce a cytokine release syndrome (CRS) and induction of treatable macrophage activation syndrome (MAS) that can be managed by the IL-6 antagonist Tocilizumab (toc). ASH Annu Meet Abstr 2012; 120: 2604.

    Google Scholar 

  6. 6

    Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ et al. Cellular immunotherapy for refractory hematological malignancies. J Transl Med 2013; 11: 150.

    CAS  Article  Google Scholar 

  7. 7

    Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M . Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 2003; 102: 2300–2307.

    CAS  Article  Google Scholar 

  8. 8

    Rubio MT, Saito TI, Kattleman K, Zhao G, Buchli J, Sykes M . Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. J Immunol 2005; 175: 665–676.

    CAS  Article  Google Scholar 

  9. 9

    Saito TI, Li HW, Sykes M . Invariant NKT cells are required for antitumor responses induced by host-versus-graft responses. J Immunol 2010; 185: 2099–2105.

    CAS  Article  Google Scholar 

  10. 10

    Symons HJ, Levy MY, Wang J, Zhou X, Zhou G, Cohen SE et al. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant 2008; 14: 499–509.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cells Biology at Rhode Island Hospital.

Author information

Affiliations

Authors

Corresponding author

Correspondence to J L Reagan.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reagan, J. Adoptive immunotherapy for myeloid malignancies. Leukemia Suppl 3, S21–S22 (2014). https://doi.org/10.1038/leusup.2014.12

Download citation

Keywords

  • allo-SCT
  • halpoidentical peripheral blood stem cells
  • minimal conditioning
  • cytokine release syndrome
  • cellular infusion

Search

Quick links